Because XLA is a monogenic disorder, correction of the singular BTK gene should result in disease correction of agammaglobulinemia, opening a promising avenue for a hematopoietic stem cell gene therapy approach to either add or restore BTK protein expression. The gene discussed is BTK; the disease is Bruton-type agammaglobulinemia.